This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXH
Zacks.com featured highlights include Franklin Electric, Insulet and Wingstop
by Zacks Equity Research
Franklin Electric, Insulet and Wingstop are part of the Zacks Screen of the Week article.
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
by Zacks Equity Research
Sector ETF report for FXH
3 Top Stocks to Buy Now for Stellar Earnings Growth
by Tirthankar Chakraborty
Stocks such as Franklin Electric (FELE), Insulet (PODD) & Wingstop (WING) have striking earnings growth and positive estimate revisions.
Abbott (ABT) EPD Business Grows Strong, Macro Issues Stay
by Zacks Equity Research
Abbott (ABT) continues to make good progress, increasing manufacturing production and recovering market share in the Nutrition business.
Zacks Industry Outlook Highlights Stryker, Boston Scientific, Zimmer Biomet and Insulet
by Zacks Equity Research
Stryker, Boston Scientific, Zimmer Biomet and Insulet are part of the Zacks Industry Outlook article.
Here's Why Investors Should Retain Syneos Health (SYNH) for Now
by Zacks Equity Research
Syneos Health's (SYNH) share price movement is expected to be favorable due to the strength of the company's Syneos One portfolio and several value-added partnership deals.
Insulet (PODD) Q1 Earnings Beat Estimates, Sales View Up
by Zacks Equity Research
Omnipod 5 continues to be a driving force of Insulet's (PODD) strong U.S. growth, representing almost 95% of U.S. new customer starts in the first quarter.
4 Medical Products Stocks to Capitalize on the Industry's Recovery
by Indrajit Bandyopadhyay
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. SYK, BSX, ZBH and PODD are well-poised to gain from the favorable factors.
Insulet (PODD) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of 155.56% and 8.45%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Buy These 5 Stocks Ahead of Earnings Releases This Week
by Nalak Das
We have narrowed our search to five stocks that are set to report earnings results this week. These are: PODD, BKNG, BILL, JCI and COLD.
Here's Why You Should Retain National Vision (EYE) Stock Now
by Zacks Equity Research
National Vision's (EYE) share price is likely to grow following the company's efforts to expand remote capabilities and investments in doctor recruiting and retention efforts.
DraftKings (DKNG) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
DraftKings' (DKNG) first-quarter 2023 performance is likely to have benefited from the robust demand for mobile sports betting and expansion efforts in new states.
BellRing Brands (BRBR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
BellRing Brands (BRBR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alcon (ALC) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Amid persistent supply-chain headwinds, Alcon's (ALC) first-quarter top-line results are likely to reflect the commercial execution of new product launches across its segments and contributions from strategic alliances.
Insulet (PODD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Insulet (PODD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Align Technology (ALGN) Q1 Earnings Beat, Margins Contract
by Zacks Equity Research
Align Technology (ALGN) delivers better-than-expected revenues and earnings in the first quarter of 2023 but suffers significant foreign currency woes.
The Zacks Analyst Blog Highlights BioRad Laboratories, Henry Schein, Insulet, Abbott and LabCorp
by Zacks Equity Research
BioRad Laboratories, Henry Schein, Insulet, Abbott and LabCorp are included in this Analyst Blog.
Illumina (ILMN) Q1 Earnings Beat Estimates, Margins Contract
by Zacks Equity Research
Illumina's (ILMN) Q1 revenues decline year over year, reflecting the impact of Covid-19 monitoring headwinds and the transition of its high-throughput customers to NovaSeq X.
SurModics (SRDX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 18.37% and 4.63%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
3 MedTech Stocks Likely to Beat Estimates in Q1 Earnings
by Urmimala Biswas
MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how BIO, HSIC and PODD are poised ahead of their earnings releases.
STERIS (STE) Set to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
STERIS' (STE) fourth-quarter fiscal 2023 results are likely to reflect an impressive performance across the Healthcare and AST segments, with a gradual improvement in the supply chain.
BioRad Laboratories (BIO) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Bio-Rad Laboratories' (BIO) first-quarter 2023 results are likely to reflect an impressive performance across its Life Science segment, with a gradual reduction in backlogs and an improvement in the supply chain.
Why Insulet (PODD) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Insulet (PODD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.